Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Multiple Myeloma 61Lymphoma, Follicular 16Recurrence 13Lymphoma, Non-Hodgkin 12Lymphoma, Mantle-Cell 12Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, B-Cell, Marginal Zone 9Lymphoma, Large B-Cell, Diffuse 8Leukemia, Lymphocytic, Chronic, B-Cell 8Waldenstrom Macroglobulinemia 7Neoplasms 7Neoplasms, Plasma Cell 6Lymphoma, Large-Cell, Anaplastic 5Leukemia, Myeloid, Acute 5Immunoblastic Lymphadenopathy 5Lymphoma, T-Cell, Cutaneous 4Hodgkin Disease 4Carcinoma, Non-Small-Cell Lung 4Sezary Syndrome 3Prostatic Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Myelodysplastic Syndromes 3Mycosis Fungoides 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, B-Cell 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Erythroblastic, Acute 3Leukemia 3

Interventions

pembrolizumab 3Carboplatin 3Nivolumab 2Injections 2Docetaxel 2Cisplatin 2BMS-753493 2zimberelimab 1urelumab 1tislelizumab 1tesetaxel 1spartalizumab 1olaparib 1liposomal doxorubicin 1linifanib 1lenvatinib 1ixabepilone 1durvalumab 1avelumab 1avdoralimab 1adavosertib 1TAS-119 1Rifampin 1N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 1Maximum Tolerated Dose 1Linoleic Acids, Conjugated 1Lapatinib 1Itraconazole 1Irinotecan 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Advanced Solid Tumors × Bortezomib × Clear all
NCT01497626 2016-02-17

Lapatinib and Bortezomib in Patients With Advanced Malignancies

Georgetown University

Phase 1 Terminated
15 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡